The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 5

Sensitivity analyses based on various exclusion criteria for neutropenia.

Excluded trial	No. of trials	No. of patients	Experimental group	Control group	RR (95% CI)	value for RR	(%)	value for heterogeneity
Cortot (2020)	7	2733	1392	1341	1.25 [1.12, 1.39]	<0.0001	48	0.07
Fukuda (2019)	7	2857	1481	1376	1.07 [0.85, 1.34]	0.56	74	0.0008
Kitagawa (2019)	7	2789	1446	1341	1.12 [0.88, 1.42]	0.37	78	0.0002
Niho (2012)	7	2720	1382	1338	1.12 [0.81, 1.55]	0.50	76	0.0004
Reck (2009)	7	2241	1172	1069	1.11 [0.82, 1.50]	0.51	78	0.0001
Reck (2010)	7	2240	1171	1069	1.08 [0.80, 1.45]	0.62	76	0.0003
Saito (2019)	7	2671	1389	1282	1.11 [0.88, 1.41]	0.37	78	0.0002
Sandler (2006)	7	2030	1074	956	1.04 [0.81, 1.33]	0.76	71	0.002